Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template

• Published in: The Journal of biological chemistry Vol. 297; no. 1; p. 100770
• Main Authors: Gordon, Calvin J., Tchesnokov, Egor P., Schinazi, Raymond F., Götte, Matthias
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2021; American Society for Biochemistry and Molecular Biology
• Subjects: Accelerated Communication; antiviral agent; coronavirus; Covid-19; drug development; mutagen; nucleoside analogue; RNA-dependent RNA polymerase; SARS-CoV-2; Covid-19; mutagen; RDV; RNA-dependent RNA polymerase; drug development; NHC; NHC-MP; coronavirus; antiviral agent; NHC-TP; SARS-CoV-2; nucleoside analogue; RdRp; Coronavirus

The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus 2 is an important target in current drug development efforts for the treatment of coronavirus disease 2019. Molnupiravir is a broad-spectrum antiviral that is an orally bioavailable prodrug of the nucleoside analog...